+

WO2008124764A1 - Nouvelles compositions contenant un lysozyme et des polysaccharides c-1/c-4, utilisation de ces dernières pour les soins buccaux, la cosmétologie et la dermatologie, la contraception, l'urologie et la gynécologie - Google Patents

Nouvelles compositions contenant un lysozyme et des polysaccharides c-1/c-4, utilisation de ces dernières pour les soins buccaux, la cosmétologie et la dermatologie, la contraception, l'urologie et la gynécologie Download PDF

Info

Publication number
WO2008124764A1
WO2008124764A1 PCT/US2008/059747 US2008059747W WO2008124764A1 WO 2008124764 A1 WO2008124764 A1 WO 2008124764A1 US 2008059747 W US2008059747 W US 2008059747W WO 2008124764 A1 WO2008124764 A1 WO 2008124764A1
Authority
WO
WIPO (PCT)
Prior art keywords
composition
composition according
lysozyme
lip
active agent
Prior art date
Application number
PCT/US2008/059747
Other languages
English (en)
Inventor
Stefano Ferrari
Original Assignee
Saint Simeon Lda
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Saint Simeon Lda filed Critical Saint Simeon Lda
Priority to CA2688736A priority Critical patent/CA2688736C/fr
Priority to EP08733173A priority patent/EP2144596A4/fr
Publication of WO2008124764A1 publication Critical patent/WO2008124764A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/72—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds
    • A61K8/73—Polysaccharides
    • A61K8/736—Chitin; Chitosan; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/40—Transferrins, e.g. lactoferrins, ovotransferrins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/44—Oxidoreductases (1)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/482—Serine endopeptidases (3.4.21)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/4873—Cysteine endopeptidases (3.4.22), e.g. stem bromelain, papain, ficin, cathepsin H
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/64—Proteins; Peptides; Derivatives or degradation products thereof
    • A61K8/66—Enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
    • C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
    • C12Y302/01017—Lysozyme (3.2.1.17)

Definitions

  • the present invention relates generally to novel compositions and use thereof in oral care, cosmetology and dermatology, contraception, urology and gynecology.
  • Lysozymes constitute a group of enzymes capable of lysing the cell walls of bacteria and other microbes. For this reason, lysozymes have been widely used as food additives and for other purposes.
  • the major source of commercially produced lysozyme is hen's egg white, which, although in widespread use, is theoretically capable of causing allergic reactions in some humans. Thus, recently, human recombinant lysozyme has been produced.
  • Chitosan and pullulan are well known polysaccharides.
  • Chitosan has many industrial, medical, pharmaceutical, and nutritional uses, including applications as anticoagulants, antiviral agents, drug carriers, cosmetic additives, dialysis membranes, orthopedic materials, wound dressings, food stabilizers and thickeners, flavor and nutrient carriers, and dietary fiber, among other uses.
  • pullulan is also widely used, for example, in pharmaceutical, veterinary, food, cosmetic or other products like films for wrapping food, aspics or jellies, and for predosed formulations like soft or hard capsules.
  • the present invention relates to a composition comprising both a content of a lysozyme and a content of a C-l/C-4 polysaccharide.
  • lysozyme denotes the family of enzymes that catalyze the hydrolysis of certain mucopolysaccharides of bacterial cell walls, and cause bacterial lysis.
  • lysozyme includes naturally-occurring lysozymes, such as hen egg white lysozyme, synthetic lysozymes and recombinant lysozymes, such as human recombinant lysozyme, as well as lysozyme salts, such as are obtained with organic and inorganic acids, especially physiologically acceptable acids, as, for example, chloridic, sulfuric, phosphoric, lactic, acetic, malic, fumaric, citric, ascorbic acids, alone or in combination.
  • C-l/C-4 polysaccharide as used herein means a polysaccharide polymer comprised of a plurality of monosaccharide units, wherein at least one of the monosaccharide units is bonded through its C-I position to the C-4 position of a second of the monosaccharide units.
  • the present invention relates to a method for caring for the oral cavity of a patient in need thereof, which involves introducing to said oral cavity or applying to an article to be introduced into said oral cavity an effective amount therefor of the inventive composition.
  • the present invention relates to a method for caring for the skin of a patient in need thereof, comprising topically applying to said skin an effective amount therefor of the inventive composition.
  • the present invention relates to a method of reducing the transmission of communicable diseases during sexual contact between two or more persons, comprising applying an effective amount therefor of the inventive composition to the sexual organs of at least one of said two or more persons and/or to an accessory protective element to be utilized during said sexual contact.
  • the inventive composition comprises a content of a lysozyme and a content of a C-l/C-4 polysaccharide.
  • lysozymes can be naturally-occurring, synthetic or recombinant. In principal, all lysozymes are useful in the inventive composition, although the intended use of the inventive composition may suggest to those skilled in the art a preference for one type of lysozyme as opposed to another.
  • the lysozyme is a human recombinant lysozyme.
  • the lysozyme is a non-human lysozyme, especially a hen egg white lysozyme.
  • C-l/C-4 polysaccharides are useful in the inventive composition, although the intended use of the inventive composition may suggest to those skilled in the art a preference for one type of C-l/C-4 polysaccharide as opposed to another.
  • the C-l/C-4 polysaccharide is selected from the group consisting of chitosan and pullulan.
  • the C-l/C-4 polysaccharide is chitosan.
  • chitosan refers to poly-(l-> 4)- ⁇ -D-glucosamine, and is inclusive of deacetylated chitin, for example, obtained by enzymatic or chemical hydrolysis, as well as the addition compounds thereof, for example, obtained with organic and inorganic acids, especially physiologically acceptable acids, for example, lactic, acetic, malic, sorbic, benzoid, glycolic, accrilic, succinic, ossalic, tartaric, citric, ascorbic acids, etc., alone or in combination.
  • Pullulan is a linear glucan produced by the so-called "black yeast" which belongs to the Deuteromycetes.
  • pullulan refers not only to this material, but also the addition compounds thereof, for example, obtained with organic and inorganic acids, especially physiologically acceptable acids, for example, lactic, acetic, malic, sorbic, benzoid, glycolic, accrilic, succinic, ossalic, tartaric, citric, ascorbic acids, etc., alone or in combination.
  • physiologically acceptable acids for example, lactic, acetic, malic, sorbic, benzoid, glycolic, accrilic, succinic, ossalic, tartaric, citric, ascorbic acids, etc., alone or in combination.
  • All the C-l/C-4 polysaccharides used according to the present invention are commercially available or readily obtainable according to well known synthetic techniques. [0012]
  • concentration of lysozyme and of C-l/C-4 polysaccharide depends on the formulation and its use.
  • the concentration of lysozyme ranges between 0.005% and 99.995% by weight based on the total weight of the composition, preferably the concentration of lysozyme could be comprised between 0.05% and 99.95% by weight.
  • the concentration of the C-l/C-4 polysaccharide, for example chitosan and/or pullulan could be between 0.005% and 99.995% by weight, preferably between 0.05% and 99.95% by weight.
  • a powder so formulated could be beneficially and conveniently applied, for instance, in the topical treatment of sores, burns and wounds.
  • the inventive composition can include one or more additional active agents.
  • the inventive composition includes one or more additional active agents selected from the group consisting of the family of transferring proteins, such as lactoferrin and ovotransferrin; the enzyme family of peroxidase, such hydrogen peroxide; a cysteine protease, such as papain; a serin protease, such as trypsin; organic acids such lipoinc acid; vitamins, such as vitamin A, D, E, C (ascorbic acid), the B group, folic acid, pantotenic acid; and minerals, such as zinc.
  • the family of transferring proteins such as lactoferrin and ovotransferrin
  • the enzyme family of peroxidase such hydrogen peroxide
  • a cysteine protease such as papain
  • a serin protease such as trypsin
  • organic acids such lipoinc acid
  • the additional active agent is lactoferrin. In another especially preferred embodiment, the additional active agent is peroxidase. In a further especially preferred embodiment, the additional active agent is papain, etc.
  • the amount of the active agent included in the composition depends on the intended application. For example, the active ingredient can be present in the composition in an amount that is 0.01 to 10 times the amount of lysozyme and chitosan or pullulan in the composition. For instance, a 25 gram pomade could contain as active ingredients 20 mg lysozyme, 200 mg chitosan and 100-1000 mg papain. [0014]
  • the inventive composition can be formulated in any one of a large number of suitable forms.
  • the inventive composition is in the form of a tablet, lozenge, pill, capsule, chewing-gum, effervescent tablet and sachet, cream, lotion, powder, gel, mask, sprayable or injectable solution, sponge, hydrosoluble and/or edible film, strip, dental floss or interdental brush, lipstick, lip balm, lip gel or lip gloss, or wound dressing, etc.
  • Edible products can include one or more flavoring agents, for example, mint, cherry, citrus or fruit flavors.
  • the inventive composition is in the form of a topical cream, lotion or gel.
  • the inventive composition is in the form of a sprayable or aerosol solution.
  • the inventive composition is in the form of a hydrosoluble and/or edible film.
  • the hydrosoluble and/or edible film optionally further includes one or more flavoring agents of the type indicated above.
  • the inventive composition is in the form of a lipstick, lip balm, lip gel or lip gloss, any of which can, as indicated above, also include a flavoring agent.
  • the inventive composition finds usefulness in a variety of end uses.
  • the inventive composition is useful in one embodiment in oral care.
  • the inventive composition is introduced into the oral cavity or applied to an article that is to be introduced into the oral cavity.
  • the amount of actives again depends on the application and the unit dosage form.
  • a therapeutically effective gum that is 16 mm in diameter and 1,750 mg in weight could contain from 10 mg to 50 mg lysozyme and from 50 mg to 90 mg of chitosan and/or pullulan.
  • a film strip could contain from 1-3 meg of lysozyme and from 3-5 meg of chitosan and/or pullulan. Again, the exact amounts for any intended application will be determined empirically based on any number of factors well known to persons skilled in the art.
  • the inventive composition is in the form of a hydrosoluble and/or edible film, and this film is introduced into the oral cavity to improve the user's breath and/or to prevent or treat an oral infection.
  • the oral infection is herpetic stomatitis. In another preferred embodiment the oral infection is gingivitis. In a third preferred embodiment the oral infection is aphtous ulcers.
  • the hydrosoluble and/or edible film includes one or more flavoring agents. All flavoring agents are suitable for this purpose. Especially preferred are mint flavors, and fruit flavors, particularly, peach and citrus fruits In a particularly preferred embodiment, the hydrosoluble and/or edible film includes a mint and/or peach flavoring.
  • the inventive composition is in the form of one or more strips, and these are applied to the gum and/or the inside of the cheeks to treat a localized disease.
  • the localized disease is a canker sore, which is also known as an aphtous ulcer.
  • the inventive composition is in the form of a film- forming solution and/or spray, which is applied to an article to be introduced into said oral cavity in order to protect, clean and/or sanitize said article.
  • this article is a removable dental product, for example, a retainer or denture.
  • This inventive compositions can also be topically applied to the skin for caring for the skin.
  • the inventive composition is in the form of a cream, lotion or hydrosoluble film.
  • the inventive composition is applied to the skin of a patient suffering from a skin infection.
  • the skin infection is acne, in particular, acnes resulting from infection by Propionibacterium acne.
  • the inventive composition is in the form of a wound dressing, which is applied to wounded skin, for example, to aid in healing of the wound.
  • the wound dressing is a wet wound dressing, for example, a hydrocolloid or hydrogel.
  • the hydrocolloid or hydrogel includes a content of a proteolytic enzyme, preferably papain.
  • the inventive composition is in the form of a lipstick lip balm, lip gel or lip gloss, and the composition is applied to the lips.
  • the patient suffers from a localized lip infection, for example, a cold sore or herpes labialis, and the inventive composition is applied to the lips as a treatment for such localized lip infection.
  • Another embodiment of the present invention relates to a method of reducing the transmission of communicable diseases during sexual contact between two or more persons.
  • the method involves applying an effective amount therefor of the inventive composition to the sexual organs of at least one of said two or more persons and/or to an accessory protective element to be utilized during said sexual contact.
  • the inventive composition is applied directly to the sex organs of at least one of said two or more persons.
  • an accessory protective element is utilized, and the composition is applied directly to said accessory protective element.
  • the accessory protective element is a condom or a contraceptive sponge.
  • the inventive composition preferably includes a content of lactoferrin.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Birds (AREA)
  • Dermatology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Virology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Medicinal Preparation (AREA)
  • Cosmetics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La présente invention concerne une composition comprenant une certaine quantité de lysozyme et une certaine quantité de polysaccharide C-1/C-4 qui est utile pour les soins buccaux, la cosmétologie et la dermatologie, la contraception, l'urologie et la gynécologie. Il est notable que cet abrégé est présenté de manière à satisfaire les règles stipulant qu'un abrégé doit permettre à un chercheur ou à tout autre lecteur d'évaluer rapidement le sujet de la divulgation technique. Il est présenté avec l'entendement qu'il ne sera pas utilisé pour interpréter ni limiter la portée ou le sens des revendications présentées en annexe. 37 CFR § 1.72(b).
PCT/US2008/059747 2007-04-10 2008-04-09 Nouvelles compositions contenant un lysozyme et des polysaccharides c-1/c-4, utilisation de ces dernières pour les soins buccaux, la cosmétologie et la dermatologie, la contraception, l'urologie et la gynécologie WO2008124764A1 (fr)

Priority Applications (2)

Application Number Priority Date Filing Date Title
CA2688736A CA2688736C (fr) 2007-04-10 2008-04-09 Nouvelles compositions renfermant du lysozyme et des polysaccharides c-1/c-4 et utilisation de celles-ci en soin oral, cosmetologie et dermatologie, contraception, urologie et gynecologie
EP08733173A EP2144596A4 (fr) 2007-04-10 2008-04-09 Nouvelles compositions contenant un lysozyme et des polysaccharides c-1/c-4, utilisation de ces dernières pour les soins buccaux, la cosmétologie et la dermatologie, la contraception, l'urologie et la gynécologie

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US91088007P 2007-04-10 2007-04-10
US60/910,880 2007-04-10

Publications (1)

Publication Number Publication Date
WO2008124764A1 true WO2008124764A1 (fr) 2008-10-16

Family

ID=39831412

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2008/059747 WO2008124764A1 (fr) 2007-04-10 2008-04-09 Nouvelles compositions contenant un lysozyme et des polysaccharides c-1/c-4, utilisation de ces dernières pour les soins buccaux, la cosmétologie et la dermatologie, la contraception, l'urologie et la gynécologie

Country Status (6)

Country Link
US (1) US8119600B2 (fr)
EP (2) EP2144596A4 (fr)
KR (1) KR20100016416A (fr)
CA (1) CA2688736C (fr)
PL (1) PL390235A1 (fr)
WO (1) WO2008124764A1 (fr)

Cited By (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011104339A1 (fr) 2010-02-25 2011-09-01 Novozymes A/S Variants d'un lysozyme et polynucléotides pour les coder
WO2012035103A1 (fr) 2010-09-16 2012-03-22 Novozymes A/S Lysozymes
WO2013076253A1 (fr) 2011-11-25 2013-05-30 Novozymes A/S Polypeptides ayant une activité de lysozyme et polynucléotides codant pour ces polypeptides
WO2013110627A1 (fr) 2012-01-23 2013-08-01 Morphosys Ag Utilisation du lysozyme comme étiquette
CN106176277A (zh) * 2016-09-06 2016-12-07 陕西慧康生物科技有限责任公司 基因重组人溶菌酶面膜及其制备方法
WO2017140807A1 (fr) 2016-02-16 2017-08-24 Monaghan Mushrooms Group Polypeptides fongiques à activité de lysozyme
CN112618451A (zh) * 2020-11-24 2021-04-09 云南云药医药研究有限公司 一种含天然抑菌成分的组合物及应用
US11859170B2 (en) 2017-05-12 2024-01-02 Novozymes A/S Polypeptides having lysozyme activity, polynucleotides encoding same and uses and compositions thereof
WO2024121324A1 (fr) 2022-12-08 2024-06-13 Novozymes A/S Polypeptide ayant une activité lysozymique et polynucléotides codant pour celui-ci
EP4470525A1 (fr) 2023-05-30 2024-12-04 Bioseutica B.V. Nouvelles formulations de gel stables pour le traitement de l'acné vulgaire

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PH12012500824A1 (en) 2009-10-26 2018-01-17 Colgate Palmolive Co Oral composition for treating oral malodor
TWI435733B (zh) 2010-01-29 2014-05-01 Colgate Palmolive Co 用於口臭控制之口腔保健調配物
US8663717B2 (en) * 2012-01-24 2014-03-04 Fontus Science, LLC Methods and delivery vehicles for providing throat relief
RU2527692C1 (ru) * 2013-07-12 2014-09-10 Владимир Николаевич Иванов Зубная паста, содержащая комплекс гидролаз
CN108379111B (zh) * 2018-05-10 2020-09-22 重庆医药高等专科学校 一种溶菌酶面膜
CN108653190A (zh) * 2018-07-09 2018-10-16 广州丽彦妆生物科技有限公司 一种可食用含溶菌酶的多效修复化妆水及其制作方法

Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030059474A1 (en) * 1999-10-18 2003-03-27 Scott Terrence L. Sustained release microspheres
US20030185869A1 (en) * 2002-02-04 2003-10-02 Elan Pharma International Ltd. Nanoparticulate compositions having lysozyme as a surface stabilizer
US20040071636A1 (en) * 1994-09-09 2004-04-15 Allan Delisle Bacteriophage-encoded enzymes for the treatment and prevention of dental caries and periodontal diseases
WO2004058231A2 (fr) * 2002-12-26 2004-07-15 University Of Manitoba Films solubles
US20050031691A1 (en) * 2002-09-11 2005-02-10 Elan Pharma International Ltd. Gel stabilized nanoparticulate active agent compositions
US20050037033A1 (en) * 2003-05-23 2005-02-17 Program For Appropriate Technology In Health Microbicidal compositions and methods and use
WO2005089416A2 (fr) * 2004-03-18 2005-09-29 State Of Oregon Acting By And Through The State Board Of Higher Education On Behalf Of Oregon State University Films en lysozyme-chitosane
US20060246029A1 (en) * 2005-03-16 2006-11-02 Procyte Corporation Methods and compositions for preventing and treating aging or photodamaged skin

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0693924B2 (fr) * 1993-02-22 2008-04-09 Abraxis BioScience, Inc. Procedes d'administration (in vivo) de substances biologiques et compositions utilisees dans ces procedes
US5592949A (en) * 1994-06-29 1997-01-14 Moench; Thomas R. Device for acidic buffering and method for inactivation of pathogens
US5928928A (en) * 1995-06-07 1999-07-27 Universiteit Van Amsterdam Human chitinase, its recombinant production, its use for decomposing chitin, its use in therapy or prophylaxis against infection diseases
WO2000015192A1 (fr) * 1998-09-17 2000-03-23 Zonagen, Inc. Procedes et substances pour gels contraceptifs bioadhesifs
AU2004226605A1 (en) * 2003-04-02 2004-10-14 Coley Pharmaceutical Group, Ltd. Immunostimulatory nucleic acid oil-in-water formulations for topical application

Patent Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040071636A1 (en) * 1994-09-09 2004-04-15 Allan Delisle Bacteriophage-encoded enzymes for the treatment and prevention of dental caries and periodontal diseases
US20030059474A1 (en) * 1999-10-18 2003-03-27 Scott Terrence L. Sustained release microspheres
US20030185869A1 (en) * 2002-02-04 2003-10-02 Elan Pharma International Ltd. Nanoparticulate compositions having lysozyme as a surface stabilizer
US20050031691A1 (en) * 2002-09-11 2005-02-10 Elan Pharma International Ltd. Gel stabilized nanoparticulate active agent compositions
WO2004058231A2 (fr) * 2002-12-26 2004-07-15 University Of Manitoba Films solubles
US20050037033A1 (en) * 2003-05-23 2005-02-17 Program For Appropriate Technology In Health Microbicidal compositions and methods and use
WO2005089416A2 (fr) * 2004-03-18 2005-09-29 State Of Oregon Acting By And Through The State Board Of Higher Education On Behalf Of Oregon State University Films en lysozyme-chitosane
US20060246029A1 (en) * 2005-03-16 2006-11-02 Procyte Corporation Methods and compositions for preventing and treating aging or photodamaged skin

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See also references of EP2144596A4 *

Cited By (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011104339A1 (fr) 2010-02-25 2011-09-01 Novozymes A/S Variants d'un lysozyme et polynucléotides pour les coder
WO2012035103A1 (fr) 2010-09-16 2012-03-22 Novozymes A/S Lysozymes
US10829751B2 (en) 2011-11-25 2020-11-10 Novozyems A/S Polypeptides having lysozyme activity and polynucleotides encoding same
US10039300B2 (en) 2011-11-25 2018-08-07 Novozymes A/S Polypeptides having lysozyme activity and compositions comprising it
US10829750B2 (en) 2011-11-25 2020-11-10 Novozymes A/S Polypeptides having lysozyme activity and polynucleotides encoding same
WO2013076253A1 (fr) 2011-11-25 2013-05-30 Novozymes A/S Polypeptides ayant une activité de lysozyme et polynucléotides codant pour ces polypeptides
US9663775B2 (en) 2011-11-25 2017-05-30 Novozymes A/S Polypeptides having lysozyme activity and polynucleotides encoding same
WO2013076259A2 (fr) 2011-11-25 2013-05-30 Novozymes A/S Polypeptides ayant une activité de lysozyme et polynucléotides codant pour ces polypeptides
US9701952B2 (en) 2011-11-25 2017-07-11 Novozymes A/S Polypeptides having lysozyme activity and polynucleotides encoding same
US10119130B2 (en) 2011-11-25 2018-11-06 Novozymes A/S Polypeptides having lysozyme activity and compositions comprising it
US9689014B2 (en) 2012-01-23 2017-06-27 Morphosys Ag Use of lysozyme as a tag
WO2013110627A1 (fr) 2012-01-23 2013-08-01 Morphosys Ag Utilisation du lysozyme comme étiquette
WO2017140807A1 (fr) 2016-02-16 2017-08-24 Monaghan Mushrooms Group Polypeptides fongiques à activité de lysozyme
US11685911B2 (en) 2016-02-16 2023-06-27 Monaghan Mushroom S Group Fungal polypeptides having lysozyme activity
CN106176277A (zh) * 2016-09-06 2016-12-07 陕西慧康生物科技有限责任公司 基因重组人溶菌酶面膜及其制备方法
US11859170B2 (en) 2017-05-12 2024-01-02 Novozymes A/S Polypeptides having lysozyme activity, polynucleotides encoding same and uses and compositions thereof
CN112618451A (zh) * 2020-11-24 2021-04-09 云南云药医药研究有限公司 一种含天然抑菌成分的组合物及应用
WO2024121324A1 (fr) 2022-12-08 2024-06-13 Novozymes A/S Polypeptide ayant une activité lysozymique et polynucléotides codant pour celui-ci
EP4470525A1 (fr) 2023-05-30 2024-12-04 Bioseutica B.V. Nouvelles formulations de gel stables pour le traitement de l'acné vulgaire

Also Published As

Publication number Publication date
US8119600B2 (en) 2012-02-21
PL390235A1 (pl) 2010-07-05
EP2826462A1 (fr) 2015-01-21
CA2688736C (fr) 2017-07-04
EP2144596A1 (fr) 2010-01-20
US20080254079A1 (en) 2008-10-16
CA2688736A1 (fr) 2008-10-16
KR20100016416A (ko) 2010-02-12
EP2144596A4 (fr) 2012-06-13

Similar Documents

Publication Publication Date Title
US8119600B2 (en) Compositions containing lysozyme and C-1/C-4 polysaccharides and use thereof in oral care, cosmetology and dermatology, contraception, urology and gynecology
CN111713498B (zh) 抗微生物组合物
US20080064711A1 (en) Composition for treating oral cavity and Mucousal infections
JP2018524400A (ja) 活性成分のためのペトロラタムベースの送達システム
CN105107007B (zh) 一种阳离子医用护创敷料及其制备方法
MX2007008079A (es) Metodo para reducir la inflamacion del tejido oral usando extracto de magnolia.
KR101253374B1 (ko) 여드름 피부 개선용 화장료 조성물
KR20150013280A (ko) 박테리아 균막을 제거하기 위한 세아프로제의 용도
KR20160108971A (ko) 여드름 개선용 화장료 조성물 및 그 제조방법
US9546407B2 (en) Mixture to increase the effectiveness of antiseptics and/or disinfectants, an agent containing the mixture, and the use of this mixture
CN106389139A (zh) 一种祛痘消痕护肤多功能制剂及其制备方法
WO2019026997A1 (fr) Film comestible
RU2494724C2 (ru) Зубная паста, содержащая лиофилизированную массу живых бифидобактерий
RU2496468C2 (ru) Зубная паста, содержащая смесь лизатов бактерий
US6251371B1 (en) Treatment of skin or mucosa inflammation by topical treatment with preparation containing dichlorobenzyl alcohol
RU2535045C1 (ru) Зубная паста, содержащая стимуляторы регенерации
RU2527691C1 (ru) Зубная паста, содержащая буферную смесь
US8961939B2 (en) Compositions and related methods for oral wellness
RU2527692C1 (ru) Зубная паста, содержащая комплекс гидролаз
JP2018100296A (ja) 抗菌組成物
CN107753931A (zh) 乳酸链球菌素、西吡氯铵和氟化钠复方啫喱的制备及应用
CN107753930A (zh) 乳酸链球菌素、西吡氯铵和氟化钠漱口水的制备及其应用
CA3170666A1 (fr) Composition pour la prevention et le traitement de la dysbiose

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 08733173

Country of ref document: EP

Kind code of ref document: A1

WWE Wipo information: entry into national phase

Ref document number: 2688736

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 390235

Country of ref document: PL

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2008733173

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 20097023472

Country of ref document: KR

Kind code of ref document: A

点击 这是indexloc提供的php浏览器服务，不要输入任何密码和下载